PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

Cristian Massacesi,1 Emmanuelle Di Tomaso,2 Patrick Urban,3 Caroline Germa,4 Cornelia Quadt,5 Lucia Trandafir,1 Paola Aimone,3 Nathalie Fretault,1 Bharani Dharan,4 Ranjana Tavorath,4 Samit Hirawat4 1Novartis Oncology, Paris, France; 2Novartis Institutes for BioMedical Research Inc, Cambridge, MA, U...

Full description

Bibliographic Details
Main Authors: Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, Aimone P, Fretault N, Dharan B, Tavorath R, Hirawat S
Format: Article
Language:English
Published: Dove Medical Press 2016-01-01
Series:OncoTargets and Therapy
Subjects:
PI3K/AKT/mTOR pathway
patient selection
biomarker
PI3K inhibitors
clinical trial design
Online Access:https://www.dovepress.com/pi3k-inhibitors-as-new-cancer-therapeutics-implications-for-clinical-t-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/pi3k-inhibitors-as-new-cancer-therapeutics-implications-for-clinical-t-peer-reviewed-article-OTT

Similar Items